oral pan-TEAD auto-palmitoylation inhibitor
tumor regression at 3 mg/kg QD
from 160k compound cell-based HTS
Mol. Cancer. Ther., Apr. 13, 2021
Vivace Therapeutics, San Mateo, CA
VT-104
The Vivace Therapeutics pan-TEAD transcription factor inhibitor, VT-104, binds to a lipid pocket on TEAD, preventing its auto-palmitoylation, similar to a previously highlighted TEAD inhibitor. In contrast to previously published TEAD…